Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

10.66EUR
11:35am EDT
Change (% chg)

€-0.17 (-1.61%)
Prev Close
€10.84
Open
€10.83
Day's High
€10.90
Day's Low
€10.66
Volume
77,201
Avg. Vol
185,177
52-wk High
€15.24
52-wk Low
€6.62

Latest Key Developments (Source: Significant Developments)

Medigene submits CTA for its first TCR clinical trial
Monday, 10 Jul 2017 09:35am EDT 

July 10 (Reuters) - MEDIGENE AG :PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT.EXPECTS TO START THIS TRIAL BY YEAR END 2017.SUBMISSION TRIGGERS FINAL MILESTONE PAYMENT OF EUR 2.0 MILLION FROM MEDIGENE TO FORMER CONTRIBUTING SHAREHOLDERS OF MEDIGENE IMMUNOTHERAPIES GMBH WITHIN NEXT FIVE MONTHS.INTENDS TO SETTLE THIS PAYMENT THROUGH ISSUANCE OF NEW SHARES FROM AUTHORIZED CAPITAL.  Full Article

Medigene sticks with guidance after Q1 operating loss
Thursday, 11 May 2017 01:30am EDT 

May 11 (Reuters) - Medigene AG :Total Q1 revenue of eur 2,609 k.EBITDA loss increased as planned to eur 3,020 k.Cash and cash equivalents of eur 48,045 k on 3/31/2017.Financial guidance for 2017 confirmed.  Full Article

Medigene COO steps down
Thursday, 11 May 2017 01:28am EDT 

May 11 (Reuters) - Medigene AG :Says Dave Lemus steps down as COO and continues cooperation in an advisory role.  Full Article

Medigene says raises 20.7 mln eur in private placement
Friday, 5 May 2017 02:37am EDT 

May 5 (Reuters) - Medigene Ag :Says successfully raises eur 20.7 million in oversubscribed private placement.Says shares were allocated to institutional investors at a price of eur 10.55 per share.Says capital increase represents approximately of 9.7% of currently outstanding shares.  Full Article

Medigene revises collaboration with Mitsui Norin
Thursday, 23 Mar 2017 09:15am EDT 

Medigene AG : Medigene revises collaboration with Mitsui Norin . Today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen . Current manufacturing and supply agreement has been mutually terminated as of March 31, 2017 . Previous agreement has been replaced by a new license agreement covering drug master file (DMF) for Veregen . As a part of arrangement to terminate existing manufacturing and supply agreement, Medigene has agreed to a one-time payment of $1.75 million to Mitsui Norin . Additional payment to Mitsui Norin for up to $0.5 million to reimburse costs of ending production is also expected in course of 2017 .No further financial details regarding new license agreement were disclosed.  Full Article

Medigene FY total revenue increases 43 pct to 9.8 mln euros
Thursday, 23 Mar 2017 02:30am EDT 

Medigene Ag : FY total revenue increases 43 pct to 9.8 million euros ($10.58 million) . Financial guidance for 2016 met . Financial guidance for 2017 reflects Medigene's alignment and continued focus on its core business of immunotherapies . 2017 revenue: planned total revenue in 2017 between 8 - 10 million euros . 2017 projected EBITDA loss of 16 - 18 million euros . For 2017 Medigene anticipates cash utilization of between 23 - 27 million euros, partly due to non-recurring effects such as investments in laboratory infrastructure . FY net loss for year was reduced by 27 pct to 9.492 million euros (2015: 12.999 million euros) .Company has sufficient financial resources to fund business operations well beyond forecast horizon of two years.  Full Article

bluebird bio and Medigene establish strategic T cell receptor alliance
Thursday, 29 Sep 2016 02:09am EDT 

Medigene AG : bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy . Medigene will be responsible for generation and delivery of TCRs using its TCR isolation and characterization platform . Medigene will receive an upfront payment of $15 million .Medigene will receive research and development funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage.  Full Article

Medigene H1 total revenue up 62 pct at 5.5 mln euros
Friday, 5 Aug 2016 01:38am EDT 

Medigene AG : H1 total revenue increased by 62 pct to 5.470 million euros (6M 2015: 3.372 million euros) . H1 cash and cash equivalents and time deposits increased by 4 pct to 48.672 million euros (12/31/2015: 46.759 million euros) . Confirms its financial guidance for fiscal year 2016 . H1 research and development expenses increased by 23 pct to 5.079 million euros (6M 2015: 4.117 million euros) .H1 EBITDA loss reduced by 6 pct to 4.011 million euros (6M 2015: 4.251 million euros).  Full Article

Medigene: grant of US patent for method for identification of CD4+ t cell antigens
Monday, 25 Jul 2016 01:30am EDT 

Medigene AG : Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens . Patent covers a rapid and efficient method for identifying tumor-specific antigens .Expected to facilitate use of neoantigens in personalized T-cell therapies.  Full Article

Medigene joins Max Delbrück Centre and Charité for first clinical TCR study in Germany
Wednesday, 29 Jun 2016 01:30am EDT 

Medigene AG :Enters into a cooperation agreement with Max Delbrück Centre for Molecular Medicine in Helmholtz Association (MDC) and the Charité - Universitätsmedizin Berlin (Charité).  Full Article

BRIEF-Medigene submits CTA for its first TCR clinical trial

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT